Back to Authors

Townley, Ryan A

0000-0002-3566-3969

Mayo Clinic

Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA.

Citations 3

Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET
Townley, Ryan , Botha, Hugo , Graff‐Radford, Jonathan , Whitwell, Jennifer , Boeve, Bradley F. , Fields, Julie A. , Drubach, Daniel A., Savica, Rodolfo , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Townley, Ryan A , Jack, Clifford R , Josephs, Keith A , Boeve, Brad , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Knopman, David S. , Jones, David T.

Brain Communications | August 17, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcab182 Get It

Abstract Posterior cortical atrophy is a neurodegenerative syndrome with a heterogeneous clinical presentation due to variable involvement of the left, right, dorsal and ventral parts of the visual system, as well as inconsistent involvement of other cognitive domains and systems. 18F-fluorodeoxyglucose (FDG)-PET is a sensitive marker for regional brain damage or dysfunction, capable of capturing the pattern of neurodegeneration at the single-participant level. We aimed to leverage these inter-individual differences on FDG-PET imaging to better understand the associations of heterogeneity of posterior cortical atrophy. We identified 91 posterior cortical atrophy participants with FDG-PET data and abstracted demographic, neurologic, neuropsychological and Alzheimer’s disease biomarker data. The mean age at reported symptom onset was 59.3 (range: 45–72 years old), with an average disease duration of 4.2 years prior to FDG-PET scan, and a mean education of 15.0 years. Females were more common than males at 1.6:1. After standard preprocessing steps, the FDG-PET scans for the cohort were entered into an unsupervised machine learning algorithm which first creates a high-dimensional space of inter-individual covariance before performing an eigen-decomposition to arrive at a low-dimensional representation. Participant values (‘eigenbrains’ or latent vectors which represent principle axes of inter-individual variation) were then compared to the clinical and biomarker data. Eight eigenbrains explained over 50% of the inter-individual differences in FDG-PET uptake with left (eigenbrain 1) and right (eigenbrain 2) hemispheric lateralization representing 24% of the variance. Furthermore, eigenbrain-loads mapped onto clinical and neuropsychological data (i.e. aphasia, apraxia and global cognition were associated with the left hemispheric eigenbrain 1 and environmental agnosia and apperceptive prosopagnosia were associated with the right hemispheric eigenbrain 2), suggesting that they captured important axes of normal and abnormal brain function. We used NeuroSynth to characterize the eigenbrains through topic-based decoding, which supported the idea that the eigenbrains map onto a diverse set of cognitive functions. These eigenbrains captured important biological and pathophysiologic data (i.e. limbic predominant eigenbrain 4 patterns being associated with older age of onset compared to frontoparietal eigenbrain 7 patterns being associated with younger age of onset), suggesting that approaches that focus on inter-individual differences may be important to better understand the variability observed within a neurodegenerative syndrome like posterior cortical atrophy.
Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation
Townley, Ryan , Polsinelli, Angelina J. , Fields, Julie A. , Graff‐Radford, Jonathan , Kantarci, Kejal , Lowe, Val J. , Rademakers, Rosa , Baker, Matt , Kumar, Neeraj , Townley, Ryan A , Kantarci, Kejal M, Rademakers, Rosa V, Baker, Matt C, Kantarci, Kejal , Machulda, Mary M. , Jones, David T. , Boeve, Bradley F.

Neurocase | June 30, 2020 | Volume: 26 | Issue: 4 | Pages: 211-219

10.1080/13554794.2020.1787458 Get It

Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes
Townley, Ryan , Graff‐Radford, Jonathan , Mantyh, William G. , Botha, Hugo , Polsinelli, Angelina J. , Przybelski, Scott A. , Makhlouf, Ahmed T. , Murray, Melissa E. , Reichard, Ross R., Savica, Rodolfo , Drubach, Daniel A., Josephs, Keith A. , Lowe, Val J. , Petersen, Ronald C. , Townley, Ryan A , Makhlouf, Ahmed T , Botha, Hugo , Murray, Melissa E , Machulda, Mary M. , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Brain Communications | May 27, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa068 Get It

Abstract We report a group of patients presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions, relatively young age of onset and positive biomarkers for Alzheimer’s pathophysiology. Atypical frontal, dysexecutive/behavioural variants and early-onset variants of Alzheimer’s disease have been previously reported, but no diagnostic criteria exist for a progressive dysexecutive syndrome. In this retrospective review, we report on 55 participants diagnosed with a clinically defined progressive dysexecutive syndrome with 18F-fluorodeoxyglucose-positron emission tomography and Alzheimer’s disease biomarkers available. Sixty-two per cent of participants were female with a mean of 15.2 years of education. The mean age of reported symptom onset was 53.8 years while the mean age at diagnosis was 57.2 years. Participants and informants commonly referred to initial cognitive symptoms as ‘memory problems’ but upon further inquiry described problems with core executive functions of working memory, cognitive flexibility and cognitive inhibitory control. Multi-domain cognitive impairment was evident in neuropsychological testing with executive dysfunction most consistently affected. The frontal and parietal regions which overlap with working memory networks consistently demonstrated hypometabolism on positron emission tomography. Genetic testing for autosomal dominant genes was negative in all eight participants tested and at least one APOE ε4 allele was present in 14/26 participants tested. EEG was abnormal in 14/17 cases with 13 described as diffuse slowing. Furthermore, CSF or neuroimaging biomarkers were consistent with Alzheimer’s disease pathophysiology, although CSF p-tau was normal in 24% of cases. Fifteen of the executive predominate participants enrolled in research neuroimaging protocols and were compared to amnestic (n = 110), visual (n = 18) and language (n = 7) predominate clinical phenotypes of Alzheimer’s disease. This revealed a consistent pattern of hypometabolism in parieto-frontal brain regions supporting executive functions with relative sparing of the medial temporal lobe (versus amnestic phenotype), occipital (versus visual phenotype) and left temporal (versus language phenotype). We propose that this progressive dysexecutive syndrome should be recognized as a distinct clinical phenotype disambiguated from behavioural presentations and not linked specifically to the frontal lobe or a particular anatomic substrate without further study. This clinical presentation can be due to Alzheimer’s disease but is likely not specific for any single aetiology. Diagnostic criteria are proposed to facilitate additional research into this understudied clinical presentation.